drugset / Trial / NCT01290133

Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)

NCT01290133

Phase 1 Completed 55 enrolled Accenture
RandomizedParallel-groupSingle-blindBasic science

Summary

The purpose of this study is to describe the safety and tolerability and pharmacokinetics of a single intravenous administration of the new, Sulfobutyl Ether-7-Beta-Cyclodextrin (Captisol™) based, formulation in Healthy Adult Subjects.

Timeline

Start
2011-05
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Vestipitant Small molecule Intravenous

Indications

No indication recorded.